CSF2 and osteoarthritis: Among disease controls, patients with systemic rheumatic diseases (n = 6) displayed a higher percentage of GM-CSF+ T cells (2.5 ± 2.3%) compared to patients with osteoarthritis (1.8 ± 1.0%) or PsA (1.0 ± 0.6%).